EDIT - 2 Reasons to Sell Editas Medicine Stock and 1 Reason to Buy It
2023-03-30 08:45:00 ET
There's a lot of excitement around the potential for gene-editing stocks because their therapies have the potential to not only treat diseases, but cure them. One such company is Editas Medicine (NASDAQ: EDIT) .
Editas focuses on CRISPR (clustered, regularly interspaced, short palindromic repeats) editing. This allows the biotech company to create molecules that edit DNA. In Editas' case, it usually uses CRISPR ex-vivo editing, meaning it takes cells and edits them outside the body before reinserting them. The clinical-stage company's lead therapy is EDIT-301, a cell therapy to treat severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
The company's stock is down more than 59% over the past year. Here are two reasons to sell this stock and one reason to buy it.
For further details see:
2 Reasons to Sell Editas Medicine Stock and 1 Reason to Buy It